Stock Update (NASDAQ:AMRN): New In Vitro Eicosapentaenoic Acid Study Data Presented by Amarin Corporation plc (ADR)

Amarin Corporation plc (ADR) (NASDAQ:AMRN) announced the presentation of findings from a new in vitro study at a peer-reviewed poster session at the American Diabetes Association Scientific Sessions in Boston, Massachusetts.

The poster, titled “Eicosapentaenoic Acid (EPA) Reduces Glucose-induced Small Dense Low-Density Lipoprotein Oxidation In Vitro in a Manner Distinct from Other Triglyceride-Lowering Agents and Vitamin E,” presents data that shows exposure to eicosapentaenoic acid (EPA), an omega-3 fatty acid, inhibited glucose-induced oxidation of small dense LDL. This study examined the effects of EPA and other triglyceride-lowering agents on human sdLDL oxidation following exposure in vitro to hyperglycemic conditions. Exposure to hyperglycemic conditions resulted in a 55% increase in human sdLDL oxidation as compared to non-glucose-treated controls as measured by a marker of oxidation (malondialdehyde (MDA)). EPA inhibited this glucose-induced sdLDL oxidation in a dose-dependent fashion and, at the highest concentration tested (10.0 µM), EPA inhibited sdLDL oxidation by 94% compared to vehicle treated (ethanol) control.

Additional studies are needed to determine if the effects of EPA shown in this study would have clinically meaningful benefit in the human body.

This poster was presented by Dr. R. Preston Mason, PhD, of Brigham and Women’s Hospital. Dr. Mason is also the President and Founder of Elucida Research. (Original Source)

Shares of Amarin Corporation closed last Friday at $2.45 . AMRN has a 1-year high of $3.33 and a 1-year low of $0.78. The stock’s 50-day moving average is $2.09 and its 200-day moving average is $1.66.

On the ratings front, Amarin Corporation has been the subject of a number of recent research reports. In a report issued on March 12, H.C. Wainwright analyst Andrew Fein upgraded AMRN to Buy, with a price target of $10, which implies an upside of 308.2% from current levels. Separately, on March 3, Oppenheimer’s Akiva Felt reiterated a Hold rating on the stock .

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Andrew Fein and Akiva Felt have a total average return of 26.7% and 35.9% respectively. Fein has a success rate of 66.2% and is ranked #109 out of 3612 analysts, while Felt has a success rate of 68.8% and is ranked #27.

Amarin Corp PLC is a biopharmaceutical company with expertise in lipid science. The Company is engaged in commercialization and development of therapeutics to improve cardiovascular health.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts